[Skip to Content]
[Skip to Content Landing]
Article
December 1980

FluorophotometryIII. Streptozocin-Treated Rats and Rats With Pancreatectomy

Author Affiliations

From the Department of Ophthalmology, University of Wisconsin School of Medicine, Madison.

Arch Ophthalmol. 1980;98(12):2235-2237. doi:10.1001/archopht.1980.01020041087021
Abstract

• To determine whether elevated vitreous fluorescence levels are a result of a direct ocular toxic effect of streptozocin or a consequence of the diabetic state, we compared hyperglycemic streptozocinand insulin-treated or non-insulintreated rats, hyperglycemic rats with pancreatectomy, and normal rats. Streptozocin, 65 mg/kg, was injected intravenously in one group of hooded rats, and pancreatectomy was performed on another group of hooded rats. Eight to 16 days later, fluorescein sodium, 16.6 mg/kg, was injected in the femoral vein of 21 hyperglycemic rats and 18 normal animals. One hour later, the aqueous, vitreous, and plasma fluorescence levels were measured using fluorophotometry. We did not find a significant difference between vitreous fluorescence levels of the hyperglycemic streptozocin- and insulintreated or non-insulin-treated and normal rats. Moreover, we did not find a significant difference between the vitreous fluorescence of hyperglycemic rats with pancreatectomy and normal rats.

References
1.
Waltman S, Krupin T, Hanish S, et al:  Alteration of the blood-retinal barrier in experimental diabetes mellitus . Arch Ophthalmol 96:878-879, 1978.Article
2.
Jones CW, Cunha-Vaz J, Zweig KO, et al:  Kinetic vitreous fluorophotometry in experimental diabetes . Arch Ophthalmol 97:1941-1943, 1979.Article
3.
Krupin T, Waltman SR, Scharp DW, et al:  Ocular fluorophotometry in streptozotocin diabetes mellitus in the rat: Effect of pancreatic islet isografts . Invest Ophthalmol Vis Sci 18:1185-1190, 1979.
4.
Von Sallmann L, Grimes P:  Histopathologic changes in the eyes and kidneys of rats with long term streptozotocin diabetes , in Bellows JG (ed): Contemporary Ophthalmology . Baltimore, Williams & Wilkins Co, 1972, pp 502-511.
5.
Kirber WM, Nichols CW, Grimes PA, et al:  A permeability defect of the retinal pigment epithelium: Occurrence in early streptozocin diabetes . Arch Ophthalmol 98:725-728, 1980.Article
6.
Tso MOM, Cunha-Vaz J, Chi-Yen S, et al:  A clinicopathological study of blood-retinal barrier in experimental diabetes . Invest Ophthalmol 18( (suppl) ):169, 1979.
7.
Livingston RB, Carter SK: Streptozotocin (NSC-85998) . National Cancer Institute Chemotherapy Fact Sheet, 1969. Bethesda, Md, National Cancer Institute, pp 1-16.
8.
Rhie FH, Blanc MH, Soeldner JS, et al:  Vitreous fluorophotometry in rats . Invest Ophthalmol Vis Sci 19( (suppl) ):167, 1980.
×